Godfrey Phillips India Limited has announced a strategic Distribution Agreement with Aspeya India Private Limited. Under this three-year agreement, Godfrey Phillips will leverage its extensive distribution network to market and re-sell Aspeya’s Nicotine Replacement Therapy (NRT) products across India. This partnership is expected to drive growth by expanding the company’s product portfolio and enhancing both its top-line and bottom-line performance.
Strategic Distribution Partnership
Godfrey Phillips India Limited officially approved a new Distribution Agreement during its board meeting held on May 15, 2026. Through this collaboration, the company will handle the distribution and re-sale of Nicotine Replacement Therapy products, which are currently marketed by Aspeya India Private Limited. The agreement is set for an initial tenure of 3 years, allowing Godfrey Phillips to utilize its established trade channels to reach a wider customer base.
Synergy and Growth Potential
The move is designed to integrate the pharmaceutical and nutraceutical offerings of Aspeya into Godfrey Phillips’ existing distribution set-up. Aspeya, which reported Rs. 795.06 lakhs in revenue from operations and a profit after tax of Rs. 19.32 lakhs for the fiscal year ended March 31, 2025, adds a new health-focused product category to the company’s repertoire. This synergy is anticipated to positively impact the company’s financial trajectory in the coming quarters.
Related Party Context
The company has clarified that the transaction is conducted at arm’s length and in the ordinary course of business. Aspeya is a member entity of the same group to which Philip Morris Global Brands Inc, USA—the foreign promoter of Godfrey Phillips—belongs. The nature of this interest is purely financial, ensuring that the alignment of interests between the entities supports mutual business expansion.
Source: BSE
